ELE-101 – Beckley Psytech’s IV formulation of psilocin
At the end of last year, Beckley Psytech announced the acquisition of life science company Eleusis.
The procurement was largely based on the potential of ELE-101, Eleusis’ IV formulation of psilocin which the team believes may have a shorter treatment duration and less variability compared with oral forms of psilocybin.
Members of Eleusis’ management team were subsequently integrated into the organisation’s C-suite, with Senior Vice President Rob Conley transitioning into Beckley Psytech’s Chief Scientific Officer.
Rob Conley brings to the table a wealth of drug development experience, having previously served as Chief Scientific Officer for Neuroscience at Eli Lilly. To discuss the potential of ELE-101 to treat major depressive disorder cost-effectively, PSYCH spoke with Beckley Psytech’s new CSO.READ MORE